Phase 1 Study to Determine the Metabolism and Clearance of Baxdrostat

Exclusion Criteria

• •Significant history or clinical manifestation of any diseases as determined by the investigator
• •Prolonged QTcF (\>450 msec)
• •Confirmed (eg, 2 consecutive measurements) systolic BP \>140 or \<90 mmHg, diastolic BP \>90 or \<50 mmHg, and pulse rate \>100 or \<45 beats per minute (bpm).
• •Postural tachycardia (ie, \>30 bpm upon standing) or orthostatic hypotension (ie, a fall in systolic BP of ≥20 mmHg or diastolic BP of ≥10 mmHg upon standing).
• •Serum potassium \>upper limit of normal (5.3 mmol/L; ULN) of the reference range and serum sodium \<lower limit of normal (135 mmol/L) of the reference range
• •Aspartate aminotransferase, alanine aminotransferase, or total bilirubin values \>1.2 × ULN.
• •A known history of porphyria, myopathy, or active liver disease
• •Use of any prescription medications
• •Corticosteroid use (systemic or extensive topical use) within 3 months prior to dosing
• •Subjects who have participated in more than 3 radiolabeled drug studies in the last 12 months